Oskar Hansson
Fundador en Cell Invent Sweden AB .
Perfil
Mr. Oskar Hansson is an Investment Associate at Abelco Investment Group and a Scientific Advisor at Cell Invent Sweden AB.
He received his graduate degree from Umea Universitet.
Cargos activos de Oskar Hansson
| Empresas | Cargo | Inicio |
|---|---|---|
Cell Invent Sweden AB
 Cell Invent Sweden AB Miscellaneous Commercial ServicesCommercial Services Cell Invent Sweden AB is a company based in Lund, Sweden that develops new human disease models based on reprogrammed Alzheimer patient cells. The Swedish company is developing phenotype-based screening methods for drug discovery, drug development, and companion diagnostics development. The company was founded in 2019 by Håkan Toresson, Camilla Orbjörn, Lennart Minthon, Oskar Hansson, and Håkan Toresson has been the CEO since 2019. | Fundador | 01/01/2019 |
Abelco Investment Group (Private Equity)
 Abelco Investment Group (Private Equity) Investment ManagersFinance Abelco Investment Group (Private Equity) (Abelco Investment Group) is a private equity division of Abelco Investment Group AB. The firm is headquartered in Stockholm, Sweden. | Analista de Capital Privado | 01/06/2021 |
Formación de Oskar Hansson.
| Umea Universitet | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Abelco Investment Group (Private Equity)
Abelco Investment Group (Private Equity) Investment ManagersFinance Abelco Investment Group (Private Equity) (Abelco Investment Group) is a private equity division of Abelco Investment Group AB. The firm is headquartered in Stockholm, Sweden. | Finance |
Cell Invent Sweden AB
Cell Invent Sweden AB Miscellaneous Commercial ServicesCommercial Services Cell Invent Sweden AB is a company based in Lund, Sweden that develops new human disease models based on reprogrammed Alzheimer patient cells. The Swedish company is developing phenotype-based screening methods for drug discovery, drug development, and companion diagnostics development. The company was founded in 2019 by Håkan Toresson, Camilla Orbjörn, Lennart Minthon, Oskar Hansson, and Håkan Toresson has been the CEO since 2019. | Commercial Services |
- Bolsa de valores
- Insiders
- Oskar Hansson
